Joint Formulary & PAD

Aripiprazole - Schizophrenia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Oral solution
  • Oro-dispersible
  • Tablets
Associated Icons :
Restrictions / Comments :
Documents :
 
 

Status 2

Amber
Formulations :
  • Intramuscular injection (IM)
Associated Icons :
Restrictions / Comments :
Important

One monthly or two monthly injecton schedule available

  • Monthly injection – Deltoid or gluteal muscle
  • Injection every 2 months – Gluteal muscle only 
Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Aripiprazole
Indication :
Schizophrenia
Group Name :
Keywords :
antipsychotics depot antipsychotics, LAI, Prolonged release, dopamine D2 partial agonist Brand Names Include
Brand Names Include :
Abilify, Abilify Maintena
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Aripiprazole is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Schizophrenia.

Committee Recommendations (2)

The Surrey Heartlands Integated Care system Area Prescribing Committee recommends the administration of depot antipsychotic injections under an AMBER shared care agreement for practices that have signed up to the agreed locally commissioned service (LCS). The AMBER shared care includes a monthly injection schedule and a schedule for injections every 2 months.
 

Surrey Heartlands ICB have developed the LCS to enable stable patients with schizophrenia to be prescribed and administered these injections through their primary care prescriber (GP). 

If a practice has not signed up to the LCS the drug remains as RED status and prescriptions will be issued by the provider.

GENERIC Aripiprazole has been considered by the PCN and has been assigned a BLUE traffic light status.

NOTE - the branded product, Abilify, was considered BLACK at the PCN in May 2017.